Biotech

All Articles

Regeneron's Opdualag rival presents 57% feedback price

.Regeneron is actually back along with long-lasting follow-up for its own LAG-3 inhibitor and also P...

AstraZeneca posts information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early look at the efficiency of its internal antibody-drug conjugate (...

iTeos- GSK's TIGIT star reveals relevant renovation

.After introducing a period 3 launch based on beneficial midstage outcomes, iTeos and also GSK are a...

More collective FDA can increase unusual ailment R&ampD: file

.The FDA must be more available and collaborative to release a surge in approvals of uncommon illnes...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and a...

Atea's COVID antiviral stops working to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually stopped working an additional COVID-19 trial, however ...

Neurocrine's bid to conserve schizophrenia possibility falls short

.Neurocrine Biosciences' mental illness plan pivot has stopped working. The biotech was actually una...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually created an overdue entrance to the radioligand gathering, paying for one hundre...

F 2G rears $100M for second effort to get brand new antifungal to market

.After F2G's very first attempt to obtain a new class of antifungal to market was actually wrecked b...

Moderna targets $1.1 B in R&ampD investing slices, falls 5 courses amidst success tensions

.Moderna has actually pledged to cut R&ampD costs by $1.1 billion through 2027. The choice to shrink...